Don't resist using U-500 insulin and pramlintide for severe insulin resistance

Clinical Diabetes

Volumn 30, Issue 2, 2012, Pages 80-84

  Valentine, Virginia ^a  

^a Diabetes Network at Northside Family Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; PRAMLINTIDE;

ARTICLE; COST CONTROL; DIET THERAPY; DISEASE SEVERITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG FORMULATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE MODIFICATION; NEEDLE; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRESCRIPTION; SYRINGE; TREATMENT OUTCOME;

EID: 84859821819     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.30.2.80     Document Type: Article

References (4)

1. Brown A, Desai M, Taneja D, Tannock LR: Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. Postgrad Med 122:163-171, 2010
2. Hirsch IB: Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med 118 (Suppl. 5A):21S-26S, 2005
3. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS: High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 15:71-79, 2009
4. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 4:51-61, 2002